Lite Strategy, Inc. Restructuring and Related Cost, Number of Positions Eliminated
Lite Strategy, Inc. (LITS) reported Restructuring and Related Cost, Number of Positions Eliminated of 11 Employee for the 12-month period ending 2024-06-30, per its 10-K filed 2024-09-19.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated · last filed 2024-09-19
- Lite Strategy, Inc. restructuring and related cost, number of positions eliminated for fiscal 2024 was 11.00 Employee.
| Period end | Restructuring and Related Cost, Number of Positions Eliminated 6 month | Restructuring and Related Cost, Number of Positions Eliminated 9 month | Restructuring and Related Cost, Number of Positions Eliminated 12 month |
|---|---|---|---|
| 2024-06-30 | 11.00 Employee 10-K · filed 2024-09-19 | ||
| 2024-03-31 | 6.00 Employee 10-Q · filed 2024-05-09 | ||
| 2023-12-31 | 6.00 Employee 10-Q · filed 2024-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |